Sinotrans Limited is reportedly facing a delay in its $5 billion Hong Kong IPO.

Insiders say that the planned $5 billion Hong Kong IPO by Sinopharm Group is facing a delay, waiting for the agricultural industry market environment to improve. Insiders say that Sinopharm's advisory team currently believes that the possibility of listing in 2027 is greater. As the information has not been made public yet, insiders requested anonymity. They say that Sinopharm had previously planned to submit the IPO application in June and hoped to go public sometime this year. However, they now say that the company plans to wait until September or later to submit the listing documents, meaning that the IPO may be delayed until next year. Insiders say that discussions are still ongoing and the specific details of the timeline may still be adjusted. A Sinopharm spokesperson said that the company will continue to evaluate its capital market strategy based on market conditions and other factors, and plan to return to the capital market at the right time.